These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 31898555)

  • 21. Liposomal Irinotecan Achieves Significant Survival and Tumor Burden Control in a Triple Negative Breast Cancer Model of Spontaneous Metastasis.
    Bernards N; Ventura M; Fricke IB; Hendriks BS; Fitzgerald J; Lee H; Zheng J
    Mol Pharm; 2018 Sep; 15(9):4132-4138. PubMed ID: 30059232
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Remediating Desmoplasia with EGFR-Targeted Photoactivable Multi-Inhibitor Liposomes Doubles Overall Survival in Pancreatic Cancer.
    Obaid G; Bano S; Thomsen H; Callaghan S; Shah N; Swain JWR; Jin W; Ding X; Cameron CG; McFarland SA; Wu J; Vangel M; Stoilova-McPhie S; Zhao J; Mino-Kenudson M; Lin C; Hasan T
    Adv Sci (Weinh); 2022 Aug; 9(24):e2104594. PubMed ID: 35748165
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Second-line and third-line therapy with nanoliposomal irinotecan (nal-IRI) in pancreatic cancer: a single-center experience and review of literature.
    Möhring C; Frontado Graffe FJ; Bartels A; Sadeghlar F; Zhou T; Mahn R; Marinova M; Feldmann G; Brossart P; Glowka TR; Kalff JC; Strassburg CP; Gonzalez-Carmona MA
    J Gastrointest Oncol; 2023 Feb; 14(1):352-365. PubMed ID: 36915455
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Parallel administration of nanoliposomal irinotecan and levo-leucovorin for pancreatic cancer.
    Takada R; Ikezawa K; Yamai T; Watsuji K; Seiki Y; Kawamoto Y; Hirao T; Higashi S; Urabe M; Kai Y; Nakabori T; Uehara H; Kotani M; Yagi T; Kimura M; Nozaki K; Takagi M; Ohkawa K
    BMC Cancer; 2023 Jul; 23(1):711. PubMed ID: 37518012
    [TBL] [Abstract][Full Text] [Related]  

  • 25. NAPOLI-1 phase 3 study of liposomal irinotecan in metastatic pancreatic cancer: Final overall survival analysis and characteristics of long-term survivors.
    Wang-Gillam A; Hubner RA; Siveke JT; Von Hoff DD; Belanger B; de Jong FA; Mirakhur B; Chen LT
    Eur J Cancer; 2019 Feb; 108():78-87. PubMed ID: 30654298
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Treatment outcomes of nanoliposomal irinotecan as second-line chemotherapy after gemcitabine and nab-paclitaxel in metastatic and recurrent pancreatic cancer.
    Mie T; Sasaki T; Okamoto T; Takeda T; Mori C; Furukawa T; Kasuga A; Matsuyama M; Ozaka M; Sasahira N
    Jpn J Clin Oncol; 2022 Dec; 52(12):1399-1407. PubMed ID: 36111430
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Hepatic arterial infusion with nanoliposomal irinotecan leads to significant regression of tumor size of colorectal liver metastases in a CC531 rat model.
    Kauffels A; Nowack H; Bohnenberger H; Spitzner M; Sprenger T; Ghadimi M; Sperling J
    Clin Exp Metastasis; 2023 Jun; 40(3):235-242. PubMed ID: 37093320
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Liposomal irinotecan in metastatic pancreatic adenocarcinoma in Asian patients: Subgroup analysis of the NAPOLI-1 study.
    Bang YJ; Li CP; Lee KH; Chiu CF; Park JO; Shan YS; Kim JS; Chen JS; Shim HJ; Rau KM; Choi HJ; Oh DY; Belanger B; Chen LT
    Cancer Sci; 2020 Feb; 111(2):513-527. PubMed ID: 31789476
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Real-World Dosing Patterns and Outcomes of Patients With Metastatic Pancreatic Cancer Treated With a Liposomal Irinotecan Regimen in the United States.
    Barzi A; Miksad R; Surinach A; Corvino FA; Wang S; Torres AZ; Mamlouk K; Pulgar S; Valderrama A; Bekaii-Saab T; Ahn D
    Pancreas; 2020 Feb; 49(2):193-200. PubMed ID: 32011529
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Is There Room for Liposomal Irinotecan in Biliary Tract Cancer? A Meta-analysis of Randomised Trials.
    Merz V; Messina C; Zecchetto C; Quinzii A; Frisinghelli M; Trentin C; Salati M; Caffo O; Melisi D
    Clin Oncol (R Coll Radiol); 2024 Feb; 36(2):87-97. PubMed ID: 38129199
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Nal-IRI with 5-fluorouracil (5-FU) and leucovorin or gemcitabine plus cisplatin in advanced biliary tract cancer - the NIFE trial (AIO-YMO HEP-0315) an open label, non-comparative, randomized, multicenter phase II study.
    Perkhofer L; Berger AW; Beutel AK; Gallmeier E; Angermeier S; Fischer von Weikersthal L; Goetze TO; Muche R; Seufferlein T; Ettrich TJ
    BMC Cancer; 2019 Oct; 19(1):990. PubMed ID: 31646981
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A real-world analysis on the efficacy and tolerability of liposomal irinotecan plus 5-fluorouracil and folinic acid in metastatic pancreatic ductal adenocarcinoma in Belgium.
    Verbruggen L; Verheggen L; Vanhoutte G; Loly C; Lybaert W; Borbath I; Vergauwe P; Hendrickx K; Debeuckelaere C; de Haar-Holleman A; Van Laethem JL; Peeters M
    Ther Adv Med Oncol; 2023; 15():17588359231181500. PubMed ID: 37600936
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Size-optimized nuclear-targeting phototherapy enhances the type I interferon response for "cold" tumor immunotherapy.
    Zhang X; Yi C; Zhang L; Zhu X; He Y; Lu H; Li Y; Tang Y; Zhao W; Chen G; Wang C; Huang S; Ouyang G; Yu D
    Acta Biomater; 2023 Mar; 159():338-352. PubMed ID: 36669551
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Nanoliposomal Irinotecan in Combination with Fluorouracil and Folinic Acid, As a New Option for Second-Line Treatment in Metastatic Pancreatic Cancer].
    Ueno M
    Gan To Kagaku Ryoho; 2020 Jun; 47(6):955-962. PubMed ID: 32541174
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Development of nanoliposomal irinotecan (nal-IRI, MM-398, PEP02) in the management of metastatic pancreatic cancer.
    Chiang NJ; Chang JY; Shan YS; Chen LT
    Expert Opin Pharmacother; 2016 Jul; 17(10):1413-20. PubMed ID: 27140876
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Plasma IL8 Is a Biomarker for TAK1 Activation and Predicts Resistance to Nanoliposomal Irinotecan in Patients with Gemcitabine-Refractory Pancreatic Cancer.
    Merz V; Zecchetto C; Santoro R; Simionato F; Sabbadini F; Mangiameli D; Piro G; Cavaliere A; Deiana M; Valenti MT; Bazan D; Fedele V; Lonardi S; Melisi D
    Clin Cancer Res; 2020 Sep; 26(17):4661-4669. PubMed ID: 32532788
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparison Between FOLFIRINOX and nal-IRI/FL as Second-line Treatment After Gemcitabine Plus Nab-paclitaxel for Pancreatic Cancer.
    Otsu T; Inokawa Y; Takami H; Hayashi M; Kurimoto K; Tanaka N; Tanaka H; Shimizu D; Hattori N; Kanda M; Tanaka C; Nakayama G; Kodera Y
    Anticancer Res; 2022 Aug; 42(8):3889-3894. PubMed ID: 35896232
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Liposomal irinotecan plus fluorouracil/leucovorin versus FOLFIRINOX as the second-line chemotherapy for patients with metastatic pancreatic cancer: a multicenter retrospective study of the Korean Cancer Study Group (KCSG).
    Park HS; Kang B; Chon HJ; Im HS; Lee CK; Kim I; Kang MJ; Hwang JE; Bae WK; Cheon J; Park JO; Hong JY; Kang JH; Kim JH; Lim SH; Kim JW; Kim JW; Yoo C; Choi HJ
    ESMO Open; 2021 Apr; 6(2):100049. PubMed ID: 33578192
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A new nanoconstruct for epidermal growth factor receptor-targeted photo-immunotherapy of ovarian cancer.
    Mir Y; Elrington SA; Hasan T
    Nanomedicine; 2013 Oct; 9(7):1114-22. PubMed ID: 23485748
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Correlation between Ferumoxytol Uptake in Tumor Lesions by MRI and Response to Nanoliposomal Irinotecan in Patients with Advanced Solid Tumors: A Pilot Study.
    Ramanathan RK; Korn RL; Raghunand N; Sachdev JC; Newbold RG; Jameson G; Fetterly GJ; Prey J; Klinz SG; Kim J; Cain J; Hendriks BS; Drummond DC; Bayever E; Fitzgerald JB
    Clin Cancer Res; 2017 Jul; 23(14):3638-3648. PubMed ID: 28159813
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.